{"id":70935,"date":"2026-05-26T14:04:11","date_gmt":"2026-05-26T12:04:11","guid":{"rendered":"https:\/\/www.schweizeroptiker.ch\/?p=70935"},"modified":"2026-05-26T14:04:11","modified_gmt":"2026-05-26T12:04:11","slug":"essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management","status":"publish","type":"post","link":"https:\/\/www.schweizeroptiker.ch\/en\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/","title":{"rendered":"EssilorLuxottica at the ARVO 2026: New long-term data strengthens evidence-based myopia management"},"content":{"rendered":"
\"\"
(Image: www.essilorluxottica.com)<\/figcaption><\/figure>\n

Together with independent research papers, a total of twelve myopia-related abstracts were presented. The presented findings from randomized clinical trials, long-term observations, real-world data and studies on combined therapeutic approaches and mechanisms of action strengthen the scientific basis for comprehensive and personalized myopia management.<\/p>\n

\u201eIntegrated evidence in myopia management means bringing together clinical studies, real-world data and a deeper understanding of mechanisms of action to achieve consistent, personalized and clinically relevant outcomes along the entire patient journey,\u201c says Olga Prenat, Head of Medical & Professional Affairs at EssilorLuxottica.<\/p>\n

Long-term data confirm sustainable effectiveness<\/strong><\/h3>\n

The presentations focused on new results from a seven-year follow-up study on Essilor Stellest lenses with high-aspheric lenslets (HAL). The study conducted in China showed sustained effectiveness in children and adolescents: Over seven years, myopia progression was reduced by an average of 2.30 dpt and axial length growth was reduced by 0.92 mm. (1) Adolescents up to 19 years of age also showed a lower risk of developing high myopia compared to single vision lenses. The results underline the importance of continuous care throughout adolescence.<\/p>\n

EssilorLuxottica also presented the results of a prospective, randomized and multi-center clinical study from the USA with children aged six to twelve years. Essilor Stellest lenses slowed myopia progression by an average of 71 percent and axial length growth by 53 percent over two years compared to single vision lenses. (2)<\/p>\n

The efficacy was shown across all age groups and baseline myopia, particularly pronounced in younger children. (3) The study also confirmed a positive safety profile with stable visual acuity and high compliance and participant retention over a two-year period. Additional analysis showed no effect on the rate of change of astigmatism over two years (4), confirming previously published results from Chinese pediatric populations. (6,7) Essilor Stellest lenses received US FDA market approval in September 2025 (8) and are currently the first and only lenses in the US with approval for specific pediatric myopia indications.<\/p>\n

Consistent results across different studies and patient groups<\/strong><\/h3>\n

The data presented at ARVO 2026 also confirmed the consistent efficacy of HAL lenses across different clinical settings and patient groups. An analysis of 26 published studies - including 17 from China - showed consistent results for Essilor Stellest lenses. In all ten studies with single vision lens control groups, axial length growth was lower in children with HAL lenses than in children with single vision lenses, regardless of study design or geographic region. (9)<\/p>\n

Real-world data presented at ARVO and later published in Ophthalmology Science(10) also confirmed the effectiveness of various myopia management lenses in everyday practice. HAL lenses with H.A.L.T. technology showed the greatest reduction in axial length growth in this retrospective cohort study. Further real-world results in children with low myopia confirmed the robust effect of the HAL approach compared to other lens designs. (11)<\/p>\n

In addition, combined approaches to myopia management have come more into focus. An independent study showed that the combination of HAL lenses with low-dose atropine over 24 months provided greater control of myopia progression than atropine treatment alone. (12) In addition, a large-scale school-based study from Shanghai suggested that integrated interventions - including HAL lenses and increased outdoor time - may help reduce the incidence of myopia and slow axial length growth in myopic and premyopic children. (13)<\/p>\n

Research for future approaches in myopia management<\/strong><\/h3>\n

ARVO 2026 also showcased EssilorLuxottica's ongoing research activities in the field of myopia development and predicting treatment outcomes. Presented studies included how the retina could use chromatic contrast to detect defocus and how retinal contrast metrics can be used to predict the effectiveness of myopia management lenses. (14,15) These findings could support the development of new lens designs in the future.<\/p>\n

With continuous investment in research and innovation, EssilorLuxottica supports opticians along the entire patient journey while continuing to drive the development of new solutions such as Essilor Stellest 2.0.<\/p>\n

Note: This communication is for scientific exchange only and does not constitute medical or therapeutic advice.<\/em><\/p>\n

Sources:<\/strong><\/h3>\n

* H.A.L.T. Highly Aspherical Lenslet Target. H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a \u201chalt\u201d or \u201cstop\u201d of myopia progression.<\/p>\n

\u2020 Essilor Stellest lens regulatory status and product availability may vary by country. U.S. FDA authorization and indications for use are based solely on clinical trial data from the U.S.<\/p>\n

\u2021 Essilor\u00ae Stellest\u00ae 2.0 lenses are currently not available in all countries, including the United States, and have not been cleared by the FDA in the U.S.<\/p>\n

    \n
  1. Li X, et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 7-year follow-up study. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 0968.<\/li>\n
  2. Shen J, et al. Two-year safety and effectiveness of Stellest lenses for slowing myopia progression in a US pediatric population. ARVO 2026; 2026 May 3-7; Denver, CO. Poster 1229-0999.<\/li>\n
  3. Lim EW, et al. Impact of age and baseline myopia on the effectiveness of Stellest lenses in a US pediatric population. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1196-0966.<\/li>\n
  4. Gelb C, et al. Safety and visual acuity outcomes of Stellest lenses: 2-year results from a US pivotal trial. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1201-0971.<\/li>\n
  5. Wong YL, et al. Comparison of 24-month astigmatism changes between Stellest and single vision lenses in US children. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1229-0967.<\/li>\n
  6. Bao J, et al. Two-year changes in cylinder power in myopic children wearing spectacle lenses with highly aspherical lenslets and single vision spectacle lenses. Investigative Ophthalmology & Visual Science. 2024 Jun 17;65(7):160-.9.<\/li>\n
  7. Wen K, et al. Effect of Three Types of Specially-Designed Myopia Control Spectacle Lenses on Astigmatism: A Two-Year Result. Ophthalmic and Physiological Optics. 2026 Apr 8:1-7. doi: 10.1007\/s44402-026-00077-5.<\/li>\n
  8. U.S. FDA. FDA authorizes marketing of first eyeglass lenses to slow progression of pediatric myopia. Sep 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia.<\/a><\/li>\n
  9. Bullimore M, et al. Myopia Control with Spectacle Lenses with Highly Aspherical Lenslets (HAL). ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 0978.<\/li>\n
  10. Ganesh SC, et al. Comparative effectiveness of myopia-control spectacle lenses: Real-world performance from a retrospective cohort study. Ophthalmology Science. 2026 Feb 2:101103.<\/li>\n
  11. Liu C, et al. Real-world effectiveness of three myopia-control spectacle lens designs in children with low myopia. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1223-0993.<\/li>\n
  12. Sim B, et al. Efficacy of Combined Highly Aspherical Lenslet Target (HALT) Spectacles and Low-Dose Atropine in Children with Poor Response to Atropine Monotherapy over 24 Months. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1002;<\/li>\n
  13. He J, et al. The School-based Myopia Prevention and Control Integrated Study in Shanghai\uff1a6-month results. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Presentation 1879.<\/li>\n
  14. Ditullio R, et al. Coloring our perspective: the importance of chromatic features in emmetropization. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 0103.<\/li>\n
  15. Hamlaoui S, et al. Predicting the efficacy of myopia control lenses by simulating their optical effect on the retina. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 4646.<\/li>\n<\/ol>\n

    Source: www.essilorluxottica.com<\/a><\/em><\/p>","protected":false},"excerpt":{"rendered":"

    EssilorLuxottica presented new clinical data and long-term results on Essilor Stellest lenses at this year's annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). <\/p>","protected":false},"author":43698,"featured_media":70938,"comment_status":"closed","ping_status":"closed","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"pgc_sgb_lightbox_settings":"","footnotes":""},"categories":[4226],"tags":[4507,4311,4322,4313],"class_list":["post-70935","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-forschungentwicklung","tag-daten","tag-forschung","tag-myopie-management","tag-studie"],"acf":[],"yoast_head":"\nEssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management - Schweizer Optiker<\/title>\n<meta name=\"description\" content=\"EssilorLuxottica hat auf der diesj\u00e4hrigen Jahrestagung der ARVO neue klinische Daten und Langzeitergebnisse zu Essilor Stellest Brillengl\u00e4sern vorgestellt.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.schweizeroptiker.ch\/en\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management\" \/>\n<meta property=\"og:description\" content=\"EssilorLuxottica hat auf der diesj\u00e4hrigen Jahrestagung der ARVO neue klinische Daten und Langzeitergebnisse zu Essilor Stellest Brillengl\u00e4sern vorgestellt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.schweizeroptiker.ch\/en\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/\" \/>\n<meta property=\"og:site_name\" content=\"Schweizer Optiker\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/schweizeroptiker\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T12:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"680\" \/>\n\t<meta property=\"og:image:height\" content=\"454\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adelisa Kalajdzini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management\" \/>\n<meta name=\"twitter:description\" content=\"#EssilorLuxottica hat auf der diesj\u00e4hrigen #Jahrestagung der #ARVO neue klinische #Daten und #Langzeitergebnisse zu Essilor #Stellest #Brillengl\u00e4sern vorgestellt.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@schweizeroptiker\" \/>\n<meta name=\"twitter:site\" content=\"@schweizeroptiker\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adelisa Kalajdzini\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/\"},\"author\":{\"name\":\"Adelisa Kalajdzini\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#\\\/schema\\\/person\\\/5352c2c070b8ef7c76a203c2450539d5\"},\"headline\":\"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management\",\"datePublished\":\"2026-05-26T12:04:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/\"},\"wordCount\":1193,\"publisher\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Bild1_ps.jpg\",\"keywords\":[\"Daten\",\"Forschung\",\"Myopie-Management\",\"Studie\"],\"articleSection\":[\"Forschung und Entwicklung\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/\",\"url\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/\",\"name\":\"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management - Schweizer Optiker\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Bild1_ps.jpg\",\"datePublished\":\"2026-05-26T12:04:11+00:00\",\"description\":\"EssilorLuxottica hat auf der diesj\u00e4hrigen Jahrestagung der ARVO neue klinische Daten und Langzeitergebnisse zu Essilor Stellest Brillengl\u00e4sern vorgestellt.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Bild1_ps.jpg\",\"contentUrl\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Bild1_ps.jpg\",\"width\":680,\"height\":454,\"caption\":\"(Bild: www.essilorluxottica.com)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/forschungentwicklung\\\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#website\",\"url\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/\",\"name\":\"Schweizer Optiker\",\"description\":\"Die kompetente Fachzeitschrift der Branche\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#organization\",\"name\":\"Schweizer Optiker\",\"url\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/logo_schweizer_optiker.png\",\"contentUrl\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/logo_schweizer_optiker.png\",\"width\":800,\"height\":229,\"caption\":\"Schweizer Optiker\"},\"image\":{\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/schweizeroptiker\\\/\",\"https:\\\/\\\/x.com\\\/schweizeroptiker\",\"https:\\\/\\\/www.linkedin.com\\\/showcase\\\/schweizeroptiker\\\/?hl=de\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/#\\\/schema\\\/person\\\/5352c2c070b8ef7c76a203c2450539d5\",\"name\":\"Adelisa Kalajdzini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g\",\"caption\":\"Adelisa Kalajdzini\"},\"url\":\"https:\\\/\\\/www.schweizeroptiker.ch\\\/en\\\/author\\\/adelisa-kalajdzini\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management - Schweizer Optiker","description":"EssilorLuxottica hat auf der diesj\u00e4hrigen Jahrestagung der ARVO neue klinische Daten und Langzeitergebnisse zu Essilor Stellest Brillengl\u00e4sern vorgestellt.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.schweizeroptiker.ch\/en\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/","og_locale":"en_US","og_type":"article","og_title":"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management","og_description":"EssilorLuxottica hat auf der diesj\u00e4hrigen Jahrestagung der ARVO neue klinische Daten und Langzeitergebnisse zu Essilor Stellest Brillengl\u00e4sern vorgestellt.","og_url":"https:\/\/www.schweizeroptiker.ch\/en\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/","og_site_name":"Schweizer Optiker","article_publisher":"https:\/\/www.facebook.com\/schweizeroptiker\/","article_published_time":"2026-05-26T12:04:11+00:00","og_image":[{"width":680,"height":454,"url":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg","type":"image\/jpeg"}],"author":"Adelisa Kalajdzini","twitter_card":"summary_large_image","twitter_title":"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management","twitter_description":"#EssilorLuxottica hat auf der diesj\u00e4hrigen #Jahrestagung der #ARVO neue klinische #Daten und #Langzeitergebnisse zu Essilor #Stellest #Brillengl\u00e4sern vorgestellt.","twitter_image":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg","twitter_creator":"@schweizeroptiker","twitter_site":"@schweizeroptiker","twitter_misc":{"Written by":"Adelisa Kalajdzini","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/#article","isPartOf":{"@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/"},"author":{"name":"Adelisa Kalajdzini","@id":"https:\/\/www.schweizeroptiker.ch\/#\/schema\/person\/5352c2c070b8ef7c76a203c2450539d5"},"headline":"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management","datePublished":"2026-05-26T12:04:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/"},"wordCount":1193,"publisher":{"@id":"https:\/\/www.schweizeroptiker.ch\/#organization"},"image":{"@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/#primaryimage"},"thumbnailUrl":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg","keywords":["Daten","Forschung","Myopie-Management","Studie"],"articleSection":["Forschung und Entwicklung"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/","url":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/","name":"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management - Schweizer Optiker","isPartOf":{"@id":"https:\/\/www.schweizeroptiker.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/#primaryimage"},"image":{"@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/#primaryimage"},"thumbnailUrl":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg","datePublished":"2026-05-26T12:04:11+00:00","description":"EssilorLuxottica hat auf der diesj\u00e4hrigen Jahrestagung der ARVO neue klinische Daten und Langzeitergebnisse zu Essilor Stellest Brillengl\u00e4sern vorgestellt.","breadcrumb":{"@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/#primaryimage","url":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg","contentUrl":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2026\/05\/Bild1_ps.jpg","width":680,"height":454,"caption":"(Bild: www.essilorluxottica.com)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.schweizeroptiker.ch\/forschungentwicklung\/essilorluxottica-auf-der-arvo-2026-neue-langzeitdaten-staerken-evidenzbasiertes-myopie-management\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.schweizeroptiker.ch\/"},{"@type":"ListItem","position":2,"name":"EssilorLuxottica auf der ARVO 2026: Neue Langzeitdaten st\u00e4rken evidenzbasiertes Myopie-Management"}]},{"@type":"WebSite","@id":"https:\/\/www.schweizeroptiker.ch\/#website","url":"https:\/\/www.schweizeroptiker.ch\/","name":"Swiss opticians","description":"The industry's expert trade journal","publisher":{"@id":"https:\/\/www.schweizeroptiker.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.schweizeroptiker.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.schweizeroptiker.ch\/#organization","name":"Swiss opticians","url":"https:\/\/www.schweizeroptiker.ch\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.schweizeroptiker.ch\/#\/schema\/logo\/image\/","url":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2024\/12\/logo_schweizer_optiker.png","contentUrl":"https:\/\/www.schweizeroptiker.ch\/wp-content\/uploads\/2024\/12\/logo_schweizer_optiker.png","width":800,"height":229,"caption":"Schweizer Optiker"},"image":{"@id":"https:\/\/www.schweizeroptiker.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/schweizeroptiker\/","https:\/\/x.com\/schweizeroptiker","https:\/\/www.linkedin.com\/showcase\/schweizeroptiker\/?hl=de"]},{"@type":"Person","@id":"https:\/\/www.schweizeroptiker.ch\/#\/schema\/person\/5352c2c070b8ef7c76a203c2450539d5","name":"Adelisa Kalajdzini","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09a397c22ac58cad6f160ee8306348599df9df58a8ede73696226897b9fa4b24?s=96&d=mm&r=g","caption":"Adelisa Kalajdzini"},"url":"https:\/\/www.schweizeroptiker.ch\/en\/author\/adelisa-kalajdzini\/"}]}},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/posts\/70935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/users\/43698"}],"replies":[{"embeddable":true,"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/comments?post=70935"}],"version-history":[{"count":2,"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/posts\/70935\/revisions"}],"predecessor-version":[{"id":70939,"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/posts\/70935\/revisions\/70939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/media\/70938"}],"wp:attachment":[{"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/media?parent=70935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/categories?post=70935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.schweizeroptiker.ch\/en\/wp-json\/wp\/v2\/tags?post=70935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}